delgocitinib
Trade name: Anzupgo
Small moleculeapproved
Approved
Jul 23, 2025
Clinical trial activity
21 trials · 3 clinical orgs · 1 marketing orgs
Phase 1
5
Phase 2
15
Phase 3
6
Phase 4
0
Earliest trial started Jan 1, 2016 (NCT02561585)
Timeline
2010s
- Jan 1, 2016
Leo Pharma — Earliest Phase 2 Sponsor(trial)
- Jan 1, 2019
Leo Pharma — Earliest Phase 1 Sponsor(trial)
2020s
- Jan 1, 2021
Leo Pharma — Earliest Phase 3 Sponsor(trial)
- Jul 23, 2025
Earliest FDA Approval
- Jul 23, 2025
Leo Pharma — Marketing Organization
Indications
Approved for
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Janus Kinase (JAK)INHIBITOR
Janus Kinase (JAK) inhibitor
Selective for the JAK family over LCK members. Some activity against ROCK-II kinase at a concentration < 1 uM. Highest affinity for JAK1 and JAK2.
Approval history
- approvedJul 23, 2025
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1CN(C(=O)CC#N)[C@]12CCN(c1ncnc3[nH]ccc13)C2- Mol. weight
- 310.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297507 ↗
Also known as
- leo 124249
- leo 124249
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07203274 | N/A | Dec 1, 2025 | Aalborg University |
| NCT07013201 | Phase 2 | Sep 11, 2025 | Leo Pharma |
| NCT06004050 | Phase 3 | Sep 5, 2023 | Leo Pharma |
| NCT05486117 | Phase 1 | Sep 6, 2022 | Leo Pharma |
| NCT05355818 | Phase 3 | Jul 14, 2022 | Leo Pharma |
| NCT05259722 | Phase 3 | Jun 15, 2022 | Leo Pharma |
| NCT05332366 | Phase 2 | Apr 19, 2022 | Leo Pharma |
| NCT05050279 | Early Phase 1 (Phase 1) | Sep 29, 2021 | Leo Pharma |
| NCT04949841 | Phase 3 | Aug 23, 2021 | Leo Pharma |
| NCT04872101 | Phase 3 | May 25, 2021 | Leo Pharma |
| NCT04871711 | Phase 3 | May 10, 2021 | Leo Pharma |
| NCT04807751 | Phase 1 | Mar 25, 2021 | Leo Pharma |
| NCT04361136 | Phase 1 | May 4, 2020 | Leo Pharma |
| NCT03958955 | Phase 2 | Jun 11, 2019 | Leo Pharma |
| NCT03826901 | Phase 1 | Feb 20, 2019 | Leo Pharma |
| NCT03725722 | Phase 2 | Dec 28, 2018 | Leo Pharma |
| NCT03683719 | Phase 2 | Oct 31, 2018 | Leo Pharma |
| NCT03325296 | Phase 2 | Oct 30, 2017 | Leo Pharma |
| NCT02695940 | Phase 2 | Mar 1, 2016 | Leo Pharma |
| NCT02664805 | Phase 2 | Feb 1, 2016 | Leo Pharma |
Showing 20 of 21 trials
Page 1 / 2
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Leo Pharma | For profit | 20 | 20 | 3 | 2016 |
| Aalborg University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Leo Pharma | For profit | MKTG | Jul 23, 2025 |